Tumor progression involves a multistep cascade in which cancer cells progressively acquire the ability to evade immune surveillance and disseminate from the primary tumor. Local invasion enables tumor cells to breach surrounding tissues, followed by intravasation into the bloodstream, where circulating tumor cells (CTCs) encounter a distinct and highly hostile immune environment.

Once in the circulation, CTCs must evade immune recognition and destruction to survive and disseminate. Interactions with platelets and other blood-borne cells can provide an additional layer of protection, shielding tumor cells from immune attack and supporting their survival and metastatic competence. Surviving CTCs subsequently undergo extravasation into distant tissues, where they establish metastatic lesions.

Metastatic disease is responsible for the majority of cancer-associated deaths, with metastases estimated to account for more than 70% of cancer mortality.

When tumor cells enter the bloodstream, platelets rapidly coat these circulating tumor cells (CTCs) and form a physical shield that can protect tumor cells from immune recognition and cytotoxic attack.

Beyond this physical protection, platelets actively modulate the immune responses through immune-regulatory receptors expressed on their surface and through the soluble immunomodulatory factors released upon activation. These signals contribute to suppression of cytotoxic T cells, NK cell activity, and macrophage responses, and promote an anti-inflammatory, immune-tolerant environment around CTCs.

Through this combination of physical shielding and active immune modulation, platelets support CTCs with a highly effective survival niche in the bloodstream, facilitating immune evasion, vascular interactions, and ultimately metastatic dissemination.

TLT-1 released by activated platelets contributes to tumor immune evasion by suppressing cytotoxic T-cell responses and innate immune activity. Blocking TLT-1 may therefore restore pro-inflammatory immune activity and enhance anti-tumor immune responses by T cells.

RANKL, produced by platelets, immune cells, and tumor cells, contributes to an immunosuppressive tumor microenvironment by modulating T-cell and Treg activity and impairing NK-cell surveillance and cytotoxic function. Inhibiting RANKL may therefore simultaneously relieve immune suppression and limit tumor-intrinsic mechanisms that support metastatic progression.

Combined TLT-1 and RANKL inhibition targets complementary mechanisms of tumor immune evasion, with the potential to restore immune recognition and cytotoxicity while reducing pro-tumor signaling.